000165115 001__ 165115
000165115 005__ 20251212165958.0
000165115 0247_ $$2doi$$a10.3390/ph18121845
000165115 0248_ $$2sideral$$a146609
000165115 037__ $$aART-2025-146609
000165115 041__ $$aeng
000165115 100__ $$0(orcid)0000-0003-2153-0417$$aAvedillo-Salas, Ana$$uUniversidad de Zaragoza
000165115 245__ $$aPrescribed Drugs and Interpersonal Violence: A Case–Non-Case Study in the Spanish Pharmacovigilance Database
000165115 260__ $$c2025
000165115 5060_ $$aAccess copy available to the general public$$fUnrestricted
000165115 5203_ $$aBackground/Objectives: Interpersonal violence is an increasing public health concern, and its prediction and prevention remain global challenges. This study aimed to identify prescribed medications associated with interpersonal violence in Spain. Methods: A descriptive, longitudinal and retrospective study and case-non case study of spontaneous reports of adverse drug reactions corresponding to interpersonal violence recorded in the Spanish Pharmacovigilance Database (FEDRA®) from 1984 to 31 March 2021. Results: 533 cases were reported in the study period. The mean age was 46.70 years with ages ranging from 1 to 99 years. There were no sex differences except in child and adolescent age group where most reports were from male. Main therapeutic groups involved were nervous system (62.3%), anti-infectives for systemic use (10%) and respiratory system (8.6%). Mostly drugs reported were montelukast, levetiracetam, bupropion, donepezil, perampanel, quetiapine, fluoxetine, and lorazepam. A statistically significant association/disproportion in the notification has been found in the reporting of interpersonal violence and different drugs according to the literature, notably atomoxetine, perampanel, memantine, donepezil, montelukast and methylphenidate. Conclusions: The results highlight that interpersonal violence, while rare, could occur as a clinically relevant adverse reaction to a small subset of medications. They underscore the importance of careful prescribing, especially in vulnerable populations and in individuals with a history of psychiatric disorders.
000165115 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000165115 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000165115 700__ $$0(orcid)0000-0001-8064-8138$$aFanlo-Villacampa, Ana$$uUniversidad de Zaragoza
000165115 700__ $$0(orcid)0000-0002-6485-1926$$aLanuza-Giménez, Francisco Javier$$uUniversidad de Zaragoza
000165115 700__ $$0(orcid)0000-0003-4629-6743$$aVicente-Romero, Jorge$$uUniversidad de Zaragoza
000165115 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000165115 773__ $$g18, 12 (2025), 1845 [19 pp.]$$pPharmaceuticals$$tPharmaceuticals$$x1424-8247
000165115 8564_ $$s1184982$$uhttps://zaguan.unizar.es/record/165115/files/texto_completo.pdf$$yVersión publicada
000165115 8564_ $$s2610347$$uhttps://zaguan.unizar.es/record/165115/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000165115 909CO $$ooai:zaguan.unizar.es:165115$$particulos$$pdriver
000165115 951__ $$a2025-12-12-14:42:58
000165115 980__ $$aARTICLE